Prognostic correlation of HLA-DR expression in large cell lymphoma as determined by LN3 antibody staining. An Eastern Cooperative Oncology Group (ECOG) study.
Several previous studies employing surface-marker techniques suggest that HLA-DR antigen expression may correlate with prognosis in diffuse large cell lymphoma. Control studies in the authors' laboratory indicated that LN3 positivity in paraffin-embedded tissue correlates well with HLA-DR antigen expression. Accordingly they examined 212 cases of diffuse large cell lymphoma from one of Eastern Cooperative Oncology Group's (ECOG) high-grade malignant lymphoma treatment protocols. All patients studied had careful clinical follow-up of between 5 and 11 1/2 years from diagnosis and initiation of therapy. There was no correlation of strongly positive, positive, weakly positive, equivocal, or negative staining with survival. Cases that were LN3 negative had a median survival of 18.8 months versus a median survival of 39.4 months for all LN3-positive cases. However this difference was not statistically significant when using a log-rank test. The authors were unable to confirm that HLA-DR antigen expression, as defined by LN3, is prognostically valuable in diffuse large cell lymphoma in a multi-institutional study.
Mallory Institute of Pathology, Boston University School of Medicine, Massachusetts.
J C
JC
O'Keane
C
C
Mack
E
E
Lynch
D
D
Harrington
R S
RS
Neiman
D000911:Antibodies, Monoclonal; D001402:B-Lymphocytes / Q000473:pathology; D005500:Follow-Up Studies; D006684:HLA-DR Antigens / Q000032:analysis*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000032:analysis / Q000473:pathology*; D015337:Multicenter Studies as Topic; D011379:Prognosis; D013194:Staining and Labeling; D015996:Survival Rate; D013601:T-Lymphocytes / Q000473:pathology
D000911:Antibodies, Monoclonal; D006684:HLA-DR Antigens